#USA #Fremont #Ultima Genomics #ppmSeq #TRACERx

Ultima Genomics Unleashes Groundbreaking Innovations in Cancer Monitoring

At the inaugural global MRD Symposium held at the AACR Annual Meeting 2026 in San Diego, Ultima Genomics presented pioneering data on their uhltrap-sensitve ppmSeq® technology. With initial TRACERx MRD data showcasing parts-per-million (ppm) performance, Ultima has made significant strides in the realm of circulating tumor DNA (ctDNA) detection. Their advancements signal a transformative moment for minimal residual disease (MRD) monitoring.

The Significance of ppmSeq Technology

Ultima Genomics has engineered the ppmSeq technology to discern tumor-derived DNA amidst a predominant background of normal DNA, eliminating the necessity for customized assays tailored for each individual patient. Gilad Almogy, Founder and CEO of Ultima Genomics, emphasized that the data revealed during the AACR symposium advocates for a future where whole-genome MRD monitoring becomes a standard practice for cancer patients worldwide.

Throughout the conference, the spotlight was on the impressive low single-digit ppm sensitivity delivered by ppmSeq across various tumor types. This groundbreaking capability stems from samples obtained through the TRACERx cancer program, a comprehensive initiative focused on studying tumor evolution, and funded by Cancer Research UK. This initiative has generated multi-region genetic data from more than 3,200 tumor samples from 800 lung cancer patients.

Professor Charles Swanton, associated with this program, pointed out that the capability to enhance ctDNA detection sensitivity is essential for broadening the scope of MRD monitoring. He highlighted the importance of assessing MRD in diverse patient populations to establish its clinical viability at a national level and beyond.

Collaboration and Validation of Results

Collaboration played a crucial role in validating the capabilities of ppmSeq. The data presented alongside partners such as LabCorp and DELFI Diagnostics reaffirmed the robustness of the technology against tailored panels commonly used in clinical settings. For instance, LabCorp shared findings from an independent study focusing on the analytical performance of an assay developed alongside ppmSeq. Their analysis revealed over 99.9% specificity for distinguishing between cancerous and non-cancerous samples, marking a notable achievement in MRD detection reliability.

Furthermore, DELFI Diagnostics presented their fragmentation-based monitoring tool, demonstrating how it works seamlessly with Ultima's platform to track treatment responses. These collaborations signify a collaborative push towards the practical application of innovative sequencing technologies in cancer genomics.

Upcoming Studies and Future Directions

The evolving landscape of MRD monitoring continues to collect momentum as Ultima prepares for future research endeavors. This includes assessing prognostic performance and exploring tumor-agnostic MRD approaches that do not require prior knowledge of a patient's mutational profile. Data from these studies is anticipated later in 2026, further solidifying the applicability of whole-genome approaches in clinical practices.

The inaugural global MRD symposium hosted by Ultima alongside distinguished figures in oncology research set the stage to collectively navigate the complexities surrounding MRD detection technologies in clinical adoption. With the goal of deploying the insights gathered from this collaboration globally, Ultima appears committed to influencing the future of cancer monitoring.

Conclusion

Ultima Genomics is leading the charge in revolutionizing the detection of minimal residual disease through the innovative ppmSeq technology and ongoing collaborations with industry pioneers. Their presentation at the AACR 2026 marks a significant milestone in cancer research, paving the way for more accessible, standardized, and effective MRD monitoring techniques for patients around the globe.